RNA viruses are responsible for numerous human diseases; some of these viruses are also potential agents of bioterrorism. In general, the replication of RNA viruses results in the incorporation of at least one mutation per round of replication, leading to a heterogeneous population, termed a quasispecies. The antiviral nucleoside ribavirin has been shown to cause an increase in the mutation frequency of RNA viruses. This increase in mutation frequency leads to a loss of viability due to error catastrophe. In this article, we review lethal mutagenesis as an antiviral strategy, emphasizing the challenges remaining for the development of lethal mutagenesis into a practical clinical approach.
The term riboviruses encompasses viruses with single-and double-stranded RNA genomes and also retroviruses, which are RNA-based for a portion of their lifecycle. Riboviruses are significant pathogens, causing diseases ranging from the common cold to exotic illnesses such as haemorrhagic fever, and also epidemic diseases such as AIDS and hepatitis C. Riboviruses are also prominent among emerging diseases (recently with SARS-associated coronavirus), and represent potential agents of bioterrorism. As such, developing effective treatments for the diseases caused by riboviruses is both a public health and homeland security priority.
Unfortunately, few effective antiviral agents exist to combat these diseases. The development of broadly effective therapeutics has been hampered by the tremendous diversity of riboviruses, as well as the ability of these viruses to rapidly adapt and acquire resistance to treatments. This adaptability is a direct reflection of the extremely high mutation frequency exhibited by riboviruses, resulting in a heterogeneous virus population or quasispecies.
Recently, compelling evidence has accumulated in support of a new antiviral strategy called 'lethal mutagenesis'. This strategy attempts to exploit the high mutation frequency of riboviruses by increasing the mutation frequency even further and driving the virus population into error catastrophe. Error catastrophe is marked by an increase in mutation frequency beyond a threshold that supports viability.
Here we review our current understanding of quasispecies, error catastrophe and lethal mutagenesis. Additionally, we describe ribavarin's mechanism of action and discuss problems that need to be overcome in order to design new and more potent lethal mutagens.
Quasispecies and error catastrophe in RNA viruses
Riboviruses display characteristically high mutation frequencies compared to DNA-based organisms. The mutation rate for riboviruses is thought to be around 10 -4 to 10 -5 mutations per nucleotide incorporated, compared to 10 -8 to 10 -11 per nucleotide incorporated for eukaryotes and prokaryotes (Domingo et al., 1996) . This results in a mutation rate of approximately 1 per genome per replication cycle for RNA viruses and 0.1 per genome per replication cycle for retroviruses. The equivalent value for DNA-based microbes is 0.003 per genome per replication cycle, even though the genome size is orders of magnitude larger (Drake & Holland, 1999) . Clearly, riboviruses are subject to extensive mutation during replication. This phenomenon is thought to be due to the absence of a proofreading activity associated with the ribovirus RNA-dependent RNA polymerases (RdRP), the enzymes responsible for replication of RNA genomes (Steinhauer et al., 1992) .
Introduction
Due to the extremely high mutation rate of riboviruses, they are postulated to exist as a quasispecies, an extremely heterogeneous population which hovers around a most-fit consensus sequence. Most or all individuals in the population will have a genome sequence differing from the consensus sequence by one or more nucleotide changes. Existence as a quasispecies implies a high degree of diversity among genomes, and thus an increased capacity for rapid adaptation to changing environmental conditions. Quasispecies theory postulates the existence of an error threshold, or an upper limit to the amount of mutation that can be tolerated by a genome. Once the error threshold is reached, even a slight increase in mutagenesis will prevent the transmission of vital genetic information. This leads to a dramatic decrease in viability mediated by mutagenesis, known as error catastrophe. If increased genetic variability in the form of a quasispecies is an important contributor to virus population fitness, then it is likely that these viruses have evolved to exist at the point of maximal adaptability. Hence, RNA viruses may exist at the error threshold.
Studies of the chemical mutagenesis of poliovirus (PV) and vesicular stomatitis virus have demonstrated that there is an upper limit to the increase in riboviruses' mutation frequency. Mutation frequencies at a single site could only be increased 1.1-to 2.8-fold, even in the presence of a mutagen that was sufficient for a 99% reduction in virus viability (Holland et al., 1990) . Thus, small increases in mutation frequency were sufficient for dramatic antiviral properties.
Crotty and coworkers, using PV as a model, indicated experimentally that RNA viruses may exist at the error threshold (Crotty et al., 2001) . Natural PV replication results in approximately 1.5 mutations per genome based on sequence analysis of capsid-coding regions. When PV was grown in the presence of a mutagen, a dramatic decline in specific infectivity of PV genomic RNA was observed when the mutation frequency exceeded two mutations per genome ( Figure 1 ). Additionally, a ~4-fold increase in mutation rate caused a 95% reduction in specific infectivity. This observation suggested that PV exists on the edge of error catastrophe and provides additional support for the notion that only a small increase in mutagenesis is necessary to allow for a potent antiviral effect.
Loeb and colleagues, using the retrovirus HIV-1, also demonstrated significant decreases in virus viability when mutation frequency was modestly increased (Loeb et al., 1999) . Serial passage of HIV-1 in the presence of a mutagen that increased the mutation rate only 3-fold was sufficient to eliminate the virus population. Subsequently, Loeb and Mullins coined the term 'lethal mutagenesis' to describe an antiviral strategy based on driving a virus to error catastrophe (Loeb & Mullins, 2000) .
Implicit in this strategy is that, even at lower mutation frequencies, serial passage in the presence of a mutagen will reduce fitness by progressive accumulation of mutations. Thus, several rounds of replication can result in virus extinction. This was demonstrated using foot-and-mouth disease virus, which was driven into extinction by a combination of mutagen and antiviral inhibitor (et al., 2001) . Recent work has shown that treatment with a mutagen alone is sufficient for eliminating foot-and-mouth disease virus (Airaksinen et al., 2003) . Thus, even moderate mutagens can possess surprisingly potent antiviral properties.
Lethal mutagenesis and the antiviral activity of ribavirin
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic purine analogue that was first synthesized in 1972 (Sidwell et al., 1972) . It has broad-spectrum antiviral activity and is effective in cultured cells against a wide range of both RNA and DNA viruses. Clinically, it is used in combination with interferon-α for treatment of hepatitis C virus (HCV) infection (Cummings et al., 2001; Davis et al., 1998) and as monotherapy for treatment of Lassa fever virus (Andrei & De Clercq, 1993; Huggins, 1989 ) and respiratory syncitial virus infections (Krilov, Mutations were introduced into PV via ribavirin treatment in cell culture. Infectivity of RNA genomes is plotted as a function of the average number of mutations per genome. Wild type PV has ~1.5 mutations per genome and is set as 100% specific infectivity. A dramatic reduction in viability is seen at mutation frequencies just slightly higher than normal. Reproduced with permission from Crotty et al. (2001) , National Academy of Sciences, USA.
2001
). It has also been used experimentally as a treatment for numerous other viruses, most recently SARS-associated coronavirus (Booth et al., 2003) .
Ribavirin (Figure 2 ) is administered as the nucleoside and, upon entering the cell, is rapidly converted to ribavirin monophosphate (RMP) by a cellular kinase. Further phosphorylation by cellular kinases leads to the accumulation of ribavirin triphosphate (RTP). RTP is the primary form of ribavirin found in exposed cells, although RMP is also present at significant levels (Miller et al., 1977; Page & Connor, 1990) .
For 30 years, the antiviral mechanism of ribavirin was thought to be due to inhibition of inosine 5′-monophosphate dehydrogenase (IMPDH) (Streeter et al., 1973) . Ribavirin monophosphate is a competitive inhibitor of IMPDH, an important enzyme in cellular nucleotide metabolism that catalyses the conversion of IMP to XMP, which is then converted to GMP (Sintchak & Nimmesgern, 2000) . XMP production is the rate-limiting and first unique step in cellular de novo synthesis of guanine nucleotides. Inhibition of IMPDH by ribavirin results in a 2-fold reduction in intracellular guanine nucleotide levels (Zimmerman & Deeprose, 1978) . Thus, the antiviral activity of ribavirin was proposed to be a function of decreased intracellular GTP. Translation, transcription and replication of RNA virus genomes is dependent upon GTP; therefore, a lack of free GTP should decrease the efficiency of these processes. Because this property of ribavirin affects the host cell and not any particular viral factor, this mechanism provided a satisfying explanation for the broad-spectrum antiviral activity of ribavirin.
Recently, it became apparent that IMPDH as the ribavirin target was insufficient to explain the antiviral activity of this compound. First, not all IMPDH inhibitors exhibit antiviral activity (Crotty et al., 2000) . Additionally, Wray and colleagues demonstrated that the reduction in GTP pools was saturated at relatively low levels of the drug and that the antiviral activity against influenza virus was seen as the concentration of ribavirin was increased beyond this level (Wray et al., 1985) . The maximum reduction in GTP in the presence of ribavirin was only 2-fold, which is likely insufficient for a strong antiviral effect. Thus, the additional antiviral activity could not be explained by GTP inhibition. Other experiments using PV as a model system showed that ribavirin had only a modest effect on translation or replication of that virus at concentrations high enough to cause significant reduction in virus viability (Crotty et al., 2000) . Lanford and coworkers showed that ribavirin has antiviral activity against GV virus B while mycophenolic acid, another IMPDH inhibitor, showed no antiviral effect (Lanford et al., 2001) . These and other experiments suggested that IMPDH inhibition, while possibly a contributing factor, was not the primary mechanism of the antiviral activity of ribavirin.
Other mechanisms of action for ribavirin have been proposed. As a GMP analogue, ribavirin has been shown to inhibit the capping reaction of Sindbis virus (Scheidel & Stollar, 1991) . In this case, a mutation in the nonstructural protein responsible for viral genome capping conferred resistance to ribavirin. However, the capping of viral RNA is not a universal process, so while this may be the primary mode of inhibition against Sindbis virus, it does not explain activity against viruses like PV and HCV that use a capindependent mechanism for translation initiation. Ribavirin triphosphate has also been shown to directly inhibit the activity of influenza virus RNA polymerase (Eriksson et al., 1977) .
Ribavirin may also act in part by modulating the host immune response. Ribavirin has been shown to promote a T-helper type 1 immune response while inhibiting a Thelper type 2 response (Tam et al., 2000) . Liver damage in HCV-infected patients is thought to be due to the immune response to infection. Inhibition of the T-helper type 2 response results in a reduction in proinflammatory cytokines and lack of macrophage activation. This may help reduce immune system-mediated damage to the liver of infected patients. Though this effect of ribavirin treatment may, in fact, impact human disease progression, it is insufficient to explain the antiviral effect of ribavirin because ribavirin exhibits antiviral activity in cell culture systems where no immune response is present. None of the aforementioned mechanisms were satisfactory to explain the broad spectrum antiviral activity of ribavirin in cell culture models. Recently, a novel mechanism of action has been suggested for ribavirin: lethal mutagenesis. By employing a primer-extension assay utilizing the RNA-dependent RNA polymerase (RdRP) from PV (3D pol ), it was shown that RTP could be recognized as an ambiguous purine analogue by a virus-encoded RdRP (Crotty et al., 2000) . Ribavirin was incorporated at approximately the same rate as an incorrect nucleotide opposite either cytidine or uridine. Additionally, a template containing ribavirin was able to direct incorporation of both cytidine and uridine at approximately the same efficiency. This promiscuous base pairing capacity is presumably due to rotation of the carboxamide moiety, resulting in two distinct hydrogen bonding configurations ( Figure 2 ). Incorporation of ribavirin as a purine analogue into the negative strand genome intermediate of PV should result in an increase of U→C and C →U transition mutations, while incorporation into the genome itself should result in G→A and A→G transitions during the next round of genome replication.
The ability of ribavirin to act as an ambiguously basepairing nucleotide suggests that it may be able to cause mutations in genomes into which it was incorporated. This was demonstrated using a guanidine resistance assay with PV. PV replication is naturally inhibited by the presence of 2 mM guanidine hydrochloride. However, resistance can be conferred by single nucleotide mutations in the 2C-coding region of the PV genome (Baltera & Tershak, 1989) . When PV was grown in HeLa cells in the presence of increasing concentrations of ribavirin, a dose-dependent increase in the frequency of guanidine resistant variants in the viable virus population was observed (Crotty et al., 2000) . This resistance was due to a single C→U transition mutation, presumably due to the incorporation of ribavirin as a purine analogue at that position in the negative strand intermediate. Importantly, there was minimal effect on translation or replication of PV RNA even when using concentrations of ribavirin that were strongly antiviral. This suggested that inhibition of IMPDH or PV 3D pol made only a minimal contribution to the observed antiviral potency of ribavirin. These experiments provided strong evidence that ribavirin was able to induce an increase in mutations in replicating virus and that its antiviral properties may be mediated, at least in part, by driving the population towards the error threshold.
Additional data has been collected in other virus systems that support lethal mutagenesis as a potential antiviral strategy. The HCV RdRP (NS5B) was shown to incorporate ribavirin in an ambiguous fashion (Maag et al., 2001) , and a full-length HCV replication system demonstrated increased mutagenesis in the presence of ribavirin (Contreras et al., 2002) . There is also evidence of increased mutation being mediated by ribavirin in an HCV subgenomic replicon system (Zhou et al., 2003 ). Lanford and colleagues were able to demonstrate that ribavirin treatment of tamarin hepatocytes infected with GV virus B (a close relative of HCV) resulted in a significant decrease in the specific infectivity of GBV-B RNA, as well as a 10 4 -fold decrease in cell-associated viral RNA (Lanford et al., 2001) . Lethal mutagenesis has also been supported in HIV-1 (Loeb et al., 1999) , foot-and-mouth disease virus (Airaksinen et al., 2003; Pariente et al., 2001) , Hantaan virus (Severson et al., 2003) and lymphocytic choriomeningitis virus (LCMV) (Ruiz-Jarabo et al., 2003) . Importantly, the above group includes riboviruses with both positive and negative strand RNA genomes, as well as a retrovirus, demonstrating the potential universality of this approach.
Incorporation of ribavirin into newly synthesized viral genomes can have additional effects beyond inducing amino acid changes in the protein coding sequence. The ambiguous base-pairing properties mediated by rotation of the carboxamide moiety can affect other processes dependent on proper recognition or pairing of nucleobases in the genome. Ribavirin present in protein-coding sequences could potentially impair codon-anticodon base pair stability and negatively impact the translation process, as well as cause errors in the amino acid sequence. Additionally, RNA structures dependent on canonical Watson-Crick pairings or Hoogsteen interactions could be weakened or disrupted. Such structures are essential for translation (for example, the internal ribosome entry site), transcription and replication, as well as for stability of the RNA.
Recently, a ribavirin-resistant population of PV was identified (Pfeiffer & Kirkegaard, 2003) . Interestingly, this population exhibited a mutation in the PV 3D pol coding region resulting in a single amino acid change. This polymerase variant was shown to display an apparent increase in fidelity and also conferred resistance to another mutagen, 5-azacytidine. Thus, increased fidelity may be a way for virus to escape lethal mutagenesis. However, the impact of increased fidelity on general viral fitness is unknown. It seems likely that RNA viruses have evolved to exist on the edge of error catastrophe due to the advantages it confers for adaptation to external challenges (for instance, the immune response or clinical intervention). Whether a high-fidelity ribovirus would be capable of vigorous replication or pathogenesis in vivo has yet to be determined.
Research by Young and colleagues has shown a similar effect in HCV using clinical samples (Young et al., 2003) . The coding region of HCV NS5B (the RdRP for this virus) was sequenced from isolates of HCV obtained from patients receiving ribavirin monotherapy. A weak mutagenic effect was noted, particularly an increase in A→G and U→A mutations. Additionally, the researchers noted a particular phenylalanine to tyrosine mutation in the thumb domain of the polymerase which emerged in all patients. This particular HCV variant was replaced by wild type virus in some patients when treatment with ribavirin was discontinued. The HCV subgenomic replicon employed in cell culture studies already contains this tyrosine mutation. However, replacing this tyrosine with phenylalanine conferred sensitivity to ribavirin in the replicon system. These results suggest that the antiviral effect of ribavirin against HCV is indeed mediated by lethal mutagenesis. The appearance of a point mutation in the polymerase coding sequence that confers resistance to ribavirin further supports the notion that the polymerase is a direct target of ribavirin treatment.
Differing results have been obtained with LCMV. Ruiz-Jarabo and colleagues demonstrated that ribavirin treatment did not increase the mutation frequency in LMCV grown in cultured cells (Ruiz-Jarabo et al., 2003) . Instead, treatment resulted in a reduction in RNA replication. In this case, ribavirin seemed to have acted as an inhibitor to the virus-encoded RdRP, as earlier described for influenza virus. However 5-fluorouracil, another mutagen, did cause an increase in mutagenesis and was able to drive LCMV into extinction. Thus, although ribavirin did not act as a lethal mutagen in this case, a different mutagen was shown to be effective in driving LCMV into error catastrophe. Additionally, this finding demonstrates that ribavirin may act via different antiviral mechanisms, depending on the virus being targeted.
Though ribavarin's mechanism of action is still being debated, it seems likely that this compound has unique antiviral properties depending on which virus is being targeted. All of the previously mentioned hypotheses (inhibition of IMPDH, the RdRP or capping enzymes, as well as lethal mutagenesis) may be correct, but each may target distinct virus families. Importantly, these different mechanisms are not mutually exclusive. IMPDH inhibition can slow the rates of translation and replication. As ribavirin is recognized as a purine analogue, IMPDH inhibition will reduce the intracellular concentration of GTP, allowing an increase in the relative efficiency of ribavirin incorporation.
Recently, a cell-based mutagenic activity has been identified as an HIV inhibitor. The protein APOBEC3G was identified as a factor that reduces the infectivity of ∆vif HIV-1 replicating in non-permissive cells (Sheehy et al., 2002) . APOBEC3G is a cytidine deaminase, which converts cytidine to uridine in DNA. Expression of this protein in Escherichia (E.) coli causes an increase in dC→dU mutations (Harris et al., 2002) . Further experiments using murine leukaemia virus suggested that the inhibitory activity of APOBEC3G was due to deamination of the first retroviral negative strand during replication and that this activity can be blocked by Vif (Harris et al., 2003) . Virus produced in non-permissive cells in the absence of Vif showed a reduction in infectivity attributed to a high degree of mutation. Thus, lethal mutagenesis may have already been adopted by nature as an innate antiviral strategy.
If lethal mutagenesis (via APOBEC3G) represents an innate antiviral response, then it is possible that there are other cellular enzymes exploiting this strategy to target foreign RNA genomes. Potential candidates are the ADAR (adenosine deaminase that acts on RNA) family of enzymes (Bass, 2002) . Two catalytically active members of this family have been identified in human cells, termed ADAR1 and ADAR2. ADAR1 is found in two distinct forms, ADAR1-long (L) and ADAR1-short (S). ADAR1-L is found in both the cytoplasm and the nucleus and is induced by interferon. ADAR1-S lacks the N-terminal 295 amino acids of ADAR1-L; it localizes to the nucleus and is constitutively expressed. The ADAR family of enzymes bind to RNA that is completely or highly double-stranded and catalyses the deamination of adenosine to inosine. ADARs have been shown to target cellular mRNA, as well as hepatitis delta virus antigenomic RNA (Polson et al., 1996) . Since inosine is generally recognized as guanosine by most enzymes, the ADARs essentially induce A→G transitions in targeted RNA sequences. The fact that ADAR1-L is highly active in the cytoplasm (Wong et al., 2003) and is expressed as part of the interferon response suggests that it may be able to catalyse mutations in viral RNA genomes replicating in the cytoplasm. It could additionally cause deviations in RNA structures that are dependent on adenosine being present in the sequence. There is evidence of viral genomes having changes consistent with editing by ADARs (Cattaneo, 1994) . Further investigation into the potential antiviral activity of the ADAR family of enzymes is warranted, as it may represent another innate, cellular antiviral defense.
In spite of the controversy over ribavarin's mechanism of action in vivo, the evidence cited above for PV and other viruses strongly supports lethal mutagenesis as a viable strategy for development of antiviral compounds. This approach may allow for the development of broad-spectrum therapies for a variety of viral diseases.
Design of lethal mutagens
Unfortunately, treatment with ribavirin and interferon-α requires high drug doses that result in undesirable side effects. Additionally, even at high doses ribavirin therapy is not always effective when employed to treat HCV. Moreover, the broad-spectrum antiviral activity observed in cell culture is not observed in the clinic. Other known mutagenic nucleosides cause extreme cytotoxicity and are generally not practical for therapeutic use. Now that it has been demonstrated that lethal mutagenesis is a viable antiviral strategy, the challenge is to develop new mutagens that can improve upon the success of ribavirin and exploit the error-prone replication of riboviruses.
Ignoring pharmacological issues, there are four major steps required for a nucleoside analogue to act as a lethal mutagen intracellularly (Figure 3): (1) transport of the nucleoside across the plasma membrane; (2) phosphorylation of the nucleoside analogue to the triphosphorylated form; (3) polymerase recognition of the triphosphate as a substrate and incorporation into the genome; and (4) ambiguous base pairing and templating properties that induce mutagenesis. Additionally, cytotoxic effects, such as those caused by inhibition of nucleoside biosynthesis pathways, should be minimized. In this section, we review briefly the current knowledge of these processes.
Intracellular transport of nucleoside analogues
In general, nucleosides have only a limited ability to passively diffuse through the cell membrane due to their primarily hydrophilic nature. (However, there are reports of particular nucleoside analogues, such as 3′-deoxy-3′-azidothymidine (AZT), entering cells through diffusion (Gourdeau et al., 2001; Hu, 1993; Zimmerman et al., 1987) . Additionally, nucleotides are unable to diffuse through biological membranes due to their highly charged phosphate groups. Rates of passive diffusion of nucleosides are dependent on the degree of hydrophobicity of the nucleoside in question. Hydrophilic nucleosides are primarily transported into the cell through the use of integral membrane proteins known as nucleoside transporters (Cabrita et al., 2002; Cass et al., 1999; Griffith & Jarvis, 1996) . Nucleoside transporters in human cells can be divided into two main categories: equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs).
ENTs are integral membrane proteins with 11 transmembrane domains that allow transport of nucleosides down their concentration gradient. The cDNA for the prototypical member of this family, hENT1, was first isolated in 1996 . hENT1 transports a broad range of nucleosides and is thought to be expressed in all cell types. The related transporter hENT2 also has broad specificity for nucleosides as well as nucleobases, but the hENT2 mRNA is not as ubiquitous as hENT1. The two related transporters also differ in their ability to transport nucleoside analogues. 3′-deoxy-nucleoside analogues were found to be poor substrates for hENT1 (Gati et al., 1984) . Because hENT2 can also transport nucleobases, it is possible that analogues with modifications to the sugar moiety may be recognized by this transporter. However, hENT1 is thought to be the major protein regulating nucleoside import in most cell types.
CNTs import nucleosides by cotransporting them with sodium against the nucleoside concentration gradient. These transporters are predicted to contain 13 transmembrane domains and a glycosylated extracellular tail. Five distinct concentrative nucleoside transport activities have been identified in human cells, and proteins responsible for three activities have been identified. CNT1 is able to uptake pyrimidine nucleosides, while CNT2 transports the purine nucleosides as well as uridine. CNT3 transports a broad range of nucleosides but requires sodium in a 2:1 ratio to nucleoside, as opposed to a 1:1 ratio for the other two characterized CNTs. Recombinant hCNT1, hCNT2, and hCNT3 have also been shown to transport nucleoside analogues (Huang et al., 1994; Ritzel et al., 2001b; Ritzel et al., 1997; Ritzel et al., 1998; Yao et al., 1997) . In general, the CNT transporters recognize antiviral nucleosides consistent with their specificities for natural nucleosides (for example, as purine analogues or pyrimidine analogues), indicating that base recognition is important for this class of transporters. hCNT3 is able to transport both purine and pyrimidine nucleoside analogues but was unable to Mutagenic ribonucleoside analogues (R) are administered extracellularly and must cross the cell membrane, generally via specific transport pathways (1). Cell-encoded kinases must then recognize and phosphorylate the nucleoside to the active triphosphate (2). During ribovirus replication, the virus-encoded RNA-dependent RNA polymerase (RdRP) must recognize the nucleotide analogue and incorporate it into nascent RNA genomes at a sufficient frequency (3). Promiscuous templating properties of the analogue must allow for the introduction of mutations (X) during subsequent rounds of copying, 'fixing' the mutation in the RNA genome (4).
Figure 3. Barriers to use of lethal mutagens
transport gancyclovir, an analogue with an acyclic ribose (Ritzel et al., 2001a) . Hence, sugar conformation may also be important in determining specificity. Concentratve nucleoside transporters are thought to be expressed only in specialized cell types, including intestinal and renal epithelia and liver .
Regulation of nucleoside transporters can occur by two mechanisms (Bradbury & Bridges, 1994) . The first is modifications to the protein itself that alter its activity (for example, phosphorylation). The other is regulation of the amount of protein present in the membrane by changing the rate of protein production or degradation. Transporters' expression levels and activity, as well as tissue-specific expression issues, will impact the ability of a given nucleoside analogue to enter and accumulate in the desired target cells.
Much research has been performed on the structurefunction relationships governing nucleoside recognition by membrane transporters. Some of the amino acid residues and protein domains that are important for specificity of transport have also been identified (Loewen et al., 1999) . Although some determinants of transporter specificity have been determined, much remains to be discovered. However, given the many varied known nucleoside transporters, it is likely that most, if not all, analogues will be transported into the cell. Also, the phosphorylation of nucleosides (as discussed in the following section) can have a concentrative effect, as the negatively-charged phosphate group should prevent diffusion out of the cell. Thus, even slow import rates may allow sufficient accumulation of nucleoside analogues. Extreme modifications to the sugar moiety, or extremely unusual or sterically bulky bases may, however, prevent cellular uptake. Further research on the structurefunction relationships determining the cellular import of nucleosides is warranted in order to elucidate properties essential for transport of analogues across the plasma membrane.
Phosphorylation of nucleoside analogues
In order to be incorporated by virus-encoded RdRPs, nucleoside analogues must be phosphorylated to the nucleoside 5′-triphosphate (NTP). Unfortunately, as mentioned above, the strongly acidic phosphate group is too hydrophilic to cross cell membranes. Additionally, phosphohydrolases present in blood and on the cell surface can remove the phosphate groups from administered nucleotides (Wagner et al., 2000) . Thus, nucleoside analogues must primarily enter the cell without any phosphate groups attached. It is therefore essential that cellular kinases recognize the analogue and phosphorylate it to the active 5′-triphosphate.
The conversion of a nucleoside to a nucleoside triphosphate occurs through a sequential series of intracellular enzymatic phosphorylation reactions (Anderson, 1973) . The first of these steps is catalysed by a variety of nucleoside kinases. Uridine-cytidine kinase catalyses uridine phosphorylation to UMP, as well as cytidine to CMP. Adenosine kinase transfers a phosphate to adenosine from ATP. Inosine-guanosine kinase is the related enzyme for guanosine phosphorylation. In general, these enzymes have broad specificity in regards to the phosphate donor. ATP is generally the preferred donor, but a number of nucleotides and nucleotide analogues may be used. Specificity for the phosphate acceptor is more strict, but a variety of nucleoside analogues are known to act as substrates for these enzymes. It seems that important characteristics are the identity of the base as well as the moiety present at the 2′-position of the ribose ring. It is important to note that nucleosides can also be broken down to liberate the free base, which can be converted to the monophosphate in a reaction with 5-phosphoribosyl 1-pyrophosphate catalysed by cellular phosphoribosyltransferases.
Nucleoside monophosphate kinases catalyse the second step in sequential phosphorylation, converting the nucleoside monophosphate (NMP) to the diphosphate (NDP) (Van Rompay et al., 2000) . A number of enzymes with varying specificities catalyse this reaction. In general, all use ATP as the highest activity phosphate donor, although other nucleoside triphosphates may be used as well. Uridylate-cytidylate kinase (UMP-CMPK) has high affinity for UMP and CMP. Five isoforms of adenylate kinase (AK) have been identified, and these catalyse the conversion of AMP to ADP. Human cells also produce a number of guanylate kinases (GUKs) which converts GMP to GDP. These enzymes also act upon the related deoxynucleosides. In general, these enzymes display high catalytic activity and conversion to the diphosphate is not generally rate limiting during metabolism to the triphosphates. The specificity of adenylate kinase appears to be influenced by both the base and the moiety at the 2′-position of the ribose.
The final step is phosphorylation of a NDP to NTP, a reaction catalysed by nucleoside diphosphate kinase (NDPK). NDPK has very broad substrate specificity, utilizing all natural ribonucleoside and deoxyribonucleosides diphosphates as substrates. The phosphate donor is a nucleoside triphosphate, usually ATP. In general, NDPK has a high catalytic efficiency, but a reduction in efficiency was seen for HIV chain terminators lacking a 3′-OH group (Bourdais et al., 1996; Schneider et al., 1998) . Since mutagenic nucleosides must have a 3′-OH to avoid inhibiting RNA synthesis, this limitation should not be important. However, heavy modifications to the pentose ring may prohibit phosphorylation by this enzyme. NDPK specificity appears to be heavily dependent on the sugar hydroxyl groups and less so on the structure of the base (Gallois-Montbrun et al., 2002) .
In general, these enzymes will phosphorylate analogues appropriate to their specific needs; for example, uridinecytidine kinase is known to phosphorylate pyrimidine analogues. Furthermore, the first step, conversion of the nucleoside to the monophosphate, is generally thought to be kinetically rate-limiting. This step may also exhibit the greatest specificity. If a nucleoside analogue is recognized by a nucleoside kinase, it is likely that enough similarity to the natural substrates exists to support subsequent phosphorylation by the nucleotide kinases, particularly the broadly specific NDPK.
Failure of a nucleoside analogue to display antiviral activity may be due to lack of intracellular phosphorylation. Because incorporation into RNA genomes requires activation to the triphosphate, failure to be recognized as a substrate for any of these enzymes will preclude antiviral activity. Tracing the metabolic fate of the analogue in question should reveal the precise point of the block.
To avoid problems associated with cell-based phosphorylation of analogues, research has been directed towards developing phosphorylated prodrugs or 'pronucleotides' (Wagner et al., 2000) . Generally, this involves modifying the compound in such a way that it can pass through the cell membrane by passive diffusion; subsequent intracellular metabolism will release the nucleotide. This approach has primarily been used to deliver the nucleoside monophosphate of a particular analogue. Although much research has been dedicated to this topic, a universal method for delivering phosphorylated nucleotide analogues has not been discovered, and little is known about how this class of drugs will generally behave in vivo.
Current methodologies allowing virus replication in cell-free extract systems are one potential way to test the mutagenic potential of a nucleoside analogue while avoiding issues of import and phosphorylation. Methods of permeabilization, both chemical (saponin and digitonin, for example) and mechanical (using physical forces to shear the plasma membrane), have been developed to allow access to the intracellular milieu. Cultured cells engineered to express broad-spectrum nucleoside and nucleotide kinases, such as herpes simplex virus type-1 (HSV-1) thymidine kinase, can also be used to eliminate problems associated with cellularly-encoded nucleoside kinase specificity. Liposomal-based drug delivery methods are another tool to navigate issues of intracellular delivery. Additionally, in vitro polymerase incorporation assays have been developed which can evaluate the rate of incorporation and base-pairing properties of nucleoside analogues. These methods should allow for the evaluation of the mutagenic potential of a nucleoside analogue in cases where delivery or phosphorylation of the analogue is limiting.
Incorporation of mutagenic nucleotides into RNA genomes
Numerous nucleoside analogues with a variety of modifications have been chemically synthesized. Many of these are mutagenic, including common analogues such as 5-fluorouridine and 5-azacytidine. Nucleosides that can cause an increase in mutagenesis can be lumped into two general categories. The first are those containing bases with no hydrogen bonding properties; they can therefore be incorporated opposite any of the naturally occurring nucleosides. The other class includes nucleosides containing bases with ambiguous hydrogen-bonding properties. Both classes of nucleoside analogues can be referred to as universal bases (Loakes, 2001) .
A number of non-hydrogen bonding nucleosides have been developed, mostly as deoxyribonucleosides (Loakes, 2001) . In general, these have hydrophobic, aromatic bases that are stable in nucleic acid duplexes due to base-stacking interactions. Because the interaction is not dependent on hydrogen bonding, these bases show little discrimination in pairing opposite any of the naturally occurring nucleosides. These analogues have shown their usefulness in degenerate primers and probes. Unfortunately, these analogues have generally been poor substrates for enzymes.
Recently, one of these universal ribonucleosides, 1-ribofuranosyl-3-nitropyrrole (3-NPN), was synthesized and investigated as a lethal mutagen against PV (Figure 4 ) (Harki et al., 2002) . The deoxyribonucleoside containing this base is known to hybridize to all four bases when in a DNA duplex (Nichols et al., 1994) . 3-NPN did not exhibit any significant antiviral effect against PV. Primer-extension assays using PV 3D pol and the triphosphorylated form of 3-NPN demonstrated that this nucleoside did in fact possess mutagenic properties, being incorporated as an analogue of either adenosine or uridine. However, it did not exhibit true universal characteristics, as it was not incorporated opposite all four natural bases. More significantly, 3-NPN was incorporated ~100-fold slower than ribavirin in this assay. Therefore, 3-NPN will be incorporated much less than once per genome during replication, making this compound an ineffective mutagen.
The results obtained with 3-NPN suggest that nonhydrogen bonding analogues may not be effective as antivirals. It is possible that hydrogen bonding interactions are necessary to stabilize the nucleoside triphosphate substrate in the active site of the polymerase for incorporation. However, the particular structure of the 3-NPN heterocyclic base may have properties that prevent effective incorporation. It may also be the case that the particular polymerase tested (PV 3D pol ) is unable to incorporate nonhydrogen bonding bases, but other polymerases are more flexible in this regard. It is possible that non-hydrogen bonding universal bases may have applications as antiviral compounds, but a variety of universal bases must be synthesized and tested for their ability to be incorporated by polymerases from different viruses.
The second major class of universal bases are those that exhibit ambiguous hydrogen bonding properties. In this case, hydrogen bonding interactions are present but different patterns of hydrogen bond donors and acceptors are displayed depending on the configuration of the molecule. Hydrogen bonding patterns can vary based on factors such as rotation, ionization and tautomerization of the base moiety. Ribavirin is an example of this class of molecule, as rotation of the carboxamide moiety allows the nucleoside to mimic either of the naturally-occurring purines. Another example is 5-fluorouridine, which can substitute as either of the naturally occurring pyrimidines (Yu et al., 1993) .
A recently synthesized analogue, termed nucleoside P (Figure 4) , acts as a pyrimidine analogue due to tautomerization of the pseudobase . The tautomeric constant (K T ) for this compound is on the order of 10-30. The two tautomers have distinct hydrogen bonding patterns that allow pairing with either guanosine or adenosine. This nucleoside was shown to induce C→U and U→C transition mutations in an in vitro retroviral replication model (Moriyama et al., 2001) . Additionally the deoxyribonucleoside of P (dP) is mutagenic to E. coli, inducing GC→AT and AT→GC transitions, and appears to be metabolized as a thymidine analogue (Negishi et al., 1997) . The 5′-triphosphate of P (PTP) is also known to be a substrate of various RNA polymerases and incorporated in place of either UTP or CTP (Moriyama et al., 1998) . Whether this compound can be used as an antiviral has yet to be determined.
Examination of the nucleoside pools in mammalian cells also provides some direction for the development of antiviral nucleosides. Intracellular pyrimidine concentrations are generally much lower than purine concentrations. Traut compiled about 600 published values for nucleoside and nucleotide concentrations (Traut, 1994) . Average concentrations of ATP and GTP in human cells are thought to be 2102 µM and 305 µM, respectively, while concentrations for the pyrimidines UTP and CTP are 253 and 91 µM. This disparity is due primarily to the extremely high intracellular concentration of ATP, indicative of its essential role as an energy source for myriad cellular processes. The development of pyrimidine analogues thus ensures that intracellular competitors are at a minimum, potentially requiring lower drug concentrations to be effective. Additionally, the purines are intimately involved in essential cellular processes beyond DNA and RNA synthesis, being necessary for metabolic processes, signaling, translation and so forth. Thus, focusing on mutagenic pyrimidine analogues may result in less adverse cellular effects.
One potential complication in developing mutagenic nucleoside analogues is the variety of targets with which a broad-spectrum antiviral must interact. Although all RdRPs are predicted to have a conserved 'right hand' structure, consisting of palm, thumb and fingers domains, the precise substrate specificity of polymerases from different virus families may vary. It is important to note that, for retroviruses, the target enzyme is the cellular RNA polymerase II. Because a host enzyme is the target in this case, this approach should greatly hinder the development of resistant retroviruses to this class of compounds.
Many nucleoside analogues have been synthesized and are known to exhibit antiviral activity (De Clercq, 1993) . Some are also known to be phosphorylated intracellularly, an essential step in utilization as a substrate for replication. In light of the recent advances in the understanding of lethal mutagens, it may be worthwhile to reexamine the mechanism of action of some of these analogues.
The development of mutagenic nucleosides that can act as substrates for virus-encoded polymerases, but not as substrates for cellular polymerases, is a lofty goal. This will prove challenging, as the specific structure-function relationships defining substrate specificities for these enzymes are still largely a mystery. Recent work with 2′modified nucleoside analogues may provide the first step in this direction . These analogues appear to be incorporated by the HCV RdRP and appear to act as chain terminators. Further experimentation demonstrated that 2′-modified nucleoside analogues were inhibitors of the HCV RdRP both in vitro and in vivo . In this case, a mutation conferring resistance was discovered in the RdRP and resistance was directed towards the specific 2′-modification. Importantly, it appeared that these nucleoside analogues were not incorporated by cellular DNA-dependent DNA polymerase or DNA-dependent RNA polymerase Migliaccio et al., 2003) . This resulted in minimal cellular toxicity at concentrations effective for virus inhibition, and intracellular phosphorylation did not appear to be rate-limiting. These promising experiments indicate that modifications to the pentose ring of the nucleoside may allow antiviral activity to be retained while reducing cytotoxicity to the host cell.
Cellular effects of mutagenic riboucleosides
Lethal mutagenesis of riboviruses is an attractive target due to the fact that ribonucleosides are used for replicating these viruses. Deoxyribonucleoside analogues, examined for use as anticancer drugs and antivirals against DNA viruses, are often extremely toxic due to their ability to be incorporated into the DNA genomes of exposed cells. Ribonucleosides eliminate this problem, as long as they are not substrates for ribonucleotide reductase, which removes the 2′-hydroxyl group of ribonucleotide diphosphates (NDPs), converting them to deoxyribonucleotide diphosphates (dNDPs). Deoxynucleotide derivative of ribavirin has not been detected in treated cells, suggesting that it is not a substrate for this enzyme (Miller et al., 1977) . Even if mutagenic analogues were to be incorporated into host cell DNA, the efficient DNA repair system present in eukaryotic cells may be able to minimize any changes to the host genome in most cases.
One of the most likely results of treatment with mutagenic ribonucleosides is incorporation into cellular RNA. Fortunately, this effect should be transient, as mRNA halflives are generally short (Ross, 1996) . Additionally, mutations made in RNA are not duplicated in new molecules, as all cellular RNA is transcribed from host cellular DNA and not by copying existing mRNAs. As mentioned in a previous section, important aspects of lethal mutagenesis include 'fixing' mutations during the next round of replication, and the accumulation of mutations through successive rounds of replication. For cellular mRNAs, each mutation will only be present in one fairly short-lived RNA molecule.
Additionally, mutations in a single RNA molecule may not have a deleterious effect on protein production due to codon 'wobble' and alternative codon usage. Mutations can, however, disrupt important RNA secondary structure or protein binding sites necessary for translation.
A potentially important cellular side effect of nucleoside analogues is the disruption of normal nucleoside/ nucleotide metabolism. Nucleoside metabolism is a complex, highly regulated process which ensures that nucleosides, as well as the mono-, di-and triphosphorylated nucleotides are present at optimal concentrations. Many known nucleotide analogues can disrupt these processes, potentially leading to adverse effects.
Ribavirin is a teratogen and has a negative effect on sperm development (Kochhar et al., 1980) . It has been suggested that this complication may be a result of ribavirin interaction with a cell-encoded RdRp . The existence of a cellular RdRP is implied from studies on RNA interference (RNAi). RNAi has been shown to be important in the development of Caenorhabditis elegans (Smardon et al., 2000) and embyogenesis in the mouse (Wianny & Zernicka-Goetz, 2000) . It is not known whether mutagenic nucleosides can disrupt these processes, but the observed side effects of ribavirin make this an interesting hypothesis. Other analogues could potentially have similar effects on development.
Conclusions
Recent developments in lethal mutagenesis have raised considerable interest in applying this concept as a new antiviral strategy. Translating this knowledge into clinical applications will prove challenging. Many unique nucleoside analogues have already been synthesized and characterized, and these should be evaluated in this new context. Furthermore, continuing advances in nucleoside chemistry should make development of effective mutagens feasible. Further research into the effects of lethal mutagens on virus populations, as well as investigations into cellular effects of mutagenic nucleoside analogues, may provide promising leads for antiviral drug development.
